Yipinhong Pharmaceutical Co Ltd Class A - Asset Resilience Ratio
Yipinhong Pharmaceutical Co Ltd Class A (300723) has an Asset Resilience Ratio of 1.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Yipinhong Pharmaceutical Co Ltd Class A current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Yipinhong Pharmaceutical Co Ltd Class A's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Yipinhong Pharmaceutical Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 300723 total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥45.33 Million | 1.01% |
| Total Liquid Assets | CN¥45.33 Million | 1.01% |
Asset Resilience Insights
- Limited Liquidity: Yipinhong Pharmaceutical Co Ltd Class A maintains only 1.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yipinhong Pharmaceutical Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Yipinhong Pharmaceutical Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Yipinhong Pharmaceutical Co Ltd Class A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Yipinhong Pharmaceutical Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.11% | CN¥4.75 Million ≈ $694.52K |
CN¥4.40 Billion ≈ $644.46 Million |
-0.81pp |
| 2023-12-31 | 0.92% | CN¥40.44 Million ≈ $5.92 Million |
CN¥4.41 Billion ≈ $644.63 Million |
-0.84pp |
| 2022-12-31 | 1.76% | CN¥72.19 Million ≈ $10.56 Million |
CN¥4.10 Billion ≈ $599.73 Million |
+1.36pp |
| 2021-12-31 | 0.41% | CN¥15.03 Million ≈ $2.20 Million |
CN¥3.70 Billion ≈ $542.07 Million |
-0.20pp |
| 2020-12-31 | 0.61% | CN¥13.00 Million ≈ $1.90 Million |
CN¥2.15 Billion ≈ $313.90 Million |
-1.38pp |
| 2019-12-31 | 1.98% | CN¥35.60 Million ≈ $5.21 Million |
CN¥1.79 Billion ≈ $262.64 Million |
-- |
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale a… Read more